News for Establishment Labs Holdings Inc. (ESTA)

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiat...

Establishment Labs Holdings Inc (ESTA), a leader in medical technology focused on women's health, has released an update on its Motiva US IDE Study, showcasing

Establishment Labs Holdings Inc. (NASDAQ: ESTA), a global medical technology company dedicated to improving women's health and wellness, principally in breast

Release Date: February 26, 2025For the complete transcript of the earnings call, please refer to the full earnings call transcript. Positive Points Establishmen

Refinitiv StreetEvents Event TranscriptE D I T E D V E R S I O NESTA.OQ - Establishment Labs Holdings IncQ4 2024 Establishment Labs Holdings Inc Earnings Call

Establishment Labs (ESTA) delivered earnings and revenue surprises of -58.06% and 0.64%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

Establishment Labs Holdings Inc (ESTA), a global leader in medical technology focused on women's health, announced its financial results for the fourth quarter

Summary Establishment Labs Holdings Inc (ESTA), a prominent global medical technology company focused on enhancing women's health, particularly in breast aesthe

Establishment Labs Holdings Inc (ESTA) is set to release its Q4 2024 earnings on Feb 26, 2025. The consensus estimate for Q4 2024 revenue is $44.61 million, and

Shares of Establishment Labs Holdings Inc (ESTA) surged 5.36% in mid-day trading on Feb 25. The stock reached an intraday high of $36.30, before settling at $

Summary Establishment Labs Holdings Inc (ESTA), a leading global medical technology company focused on women's health, particularly in breast aesthetics and rec

Establishment Labs Holdings Inc. (NASDAQ: ESTA), a global medical technology company dedicated to improving women's health and wellness in breast aesthetics an

On December 31, 2024, Nantahala Capital Management, LLC (Trades, Portfolio) executed a significant transaction involving Soleno Therapeutics Inc. The firm added

Significant Transaction on December 31, 2024 On December 31, 2024, Nantahala Capital Management, LLC (Trades, Portfolio) executed a notable reduction in its hol

Significant Transaction in Surrozen Inc On December 31, 2024, Nantahala Capital Management, LLC (Trades, Portfolio) executed a notable transaction involving Sur

Transaction Overview On December 31, 2024, Nantahala Capital Management, LLC (Trades, Portfolio) made a significant move by increasing its stake in Altisource P

On December 31, 2024, Nantahala Capital Management, LLC (Trades, Portfolio) made a strategic move by acquiring 3,493,235 shares of Apyx Medical Corp (APYX) at a

Transaction Overview On December 31, 2024, Nantahala Capital Management, LLC (Trades, Portfolio) made a strategic decision to reduce its holdings in Cellectar B

Significant Transaction on December 31, 2024 On December 31, 2024, Nantahala Capital Management, LLC (Trades, Portfolio) executed a noteworthy transaction by ac